Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial
DIABETES OBESITY & METABOLISM（2022）
关键词
antiobesity drug, clinical trial, GLP-1 analogue, obesity therapy, phase III study, weight control
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要